Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 4, 2026

Esperion to acquire Corstasis for cardiovascular franchise expansion

Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray.

Enbumyst offers a self-administered outpatient option that may bridge the gap between oral and intravenous diuretic therapies. Credit: ADDICTIVE STOCK / Shutterstock.com.